SCHEDULE 13D/A: BioRestorative Therapies Grants CEO Lance Alstodt Significant Stock Option Package

BioRestorative Therapies, Inc. has granted its CEO, Lance Alstodt, a ten-year option to purchase 791,885 shares of common stock at an exercise price of $2.46 per share, significantly increasing his beneficial ownership to 15.5%.

Summary

• BioRestorative Therapies, Inc. granted its CEO, President, and Chairman, Lance Alstodt, an incentive stock option to purchase 791,885 shares of common stock.
• The option has an exercise price of $2.46 per share and an expiration date of February 14, 2035.
• 50% of the option shares (395,943 shares) vested immediately on the grant date of February 14, 2025.
• The remaining 50% (395,942 shares) will vest in eight nearly equal quarterly installments, commencing one year from the grant date.
• As of February 18, 2025, Lance Alstodt beneficially owns 1,236,809 shares, representing approximately 15.5% of the company's outstanding common stock.
• This beneficial ownership includes 1,064,937 shares issuable upon the exercise of options currently exercisable or within 60 days.

Sentiment

Score: 7

Explanation: The grant of a significant stock option package to the CEO is generally positive as it aligns management's interests with shareholders and incentivizes long-term performance. However, it also introduces potential future dilution.

Positives

• The grant of a significant stock option package to the CEO aligns management's interests with those of shareholders, incentivizing long-term performance and share price appreciation.
• The immediate vesting of 50% of the options provides an immediate incentive, while the staggered vesting of the remainder encourages continued commitment.
• The increase in the CEO's beneficial ownership to 15.5% demonstrates a strong personal stake in the company's success.

Negatives

• The exercise of these options will result in dilution for existing shareholders, as new shares will be issued.
• The option grant itself does not provide immediate cash flow to the company.

Risks

• Dilution Risk: Exercise of the options will increase the number of outstanding shares, potentially diluting the ownership percentage of existing shareholders.
• Market Price Volatility: The value of the option is directly tied to the company's stock price, which is subject to market fluctuations and may not exceed the exercise price.
• Tax Implications: The participant bears the ultimate liability for all tax-related items, and the company makes no guarantee that the option will qualify as an Incentive Stock Option, which could lead to adverse tax consequences for the participant.
• Forfeiture Risk: Unvested portions of the option are subject to forfeiture upon termination of service for most reasons.

Future Outlook

The option's vesting schedule, with 50% vesting immediately and the remainder vesting quarterly over two years starting one year from the grant date, indicates a structured long-term incentive plan for the CEO. The ten-year expiration period provides a significant window for the CEO to realize value from the options, aligning his incentives with the company's long-term growth and share price appreciation.

Management Comments

• The grant of the incentive stock option reflects the company's decision to incentivize its Chief Executive Officer, President, and Chairman of the Board, Lance Alstodt, aligning his interests with long-term shareholder value creation.

Industry Context

Executive stock option grants are a common practice across industries, including biotechnology, to align the interests of key executives with shareholders. This grant is consistent with typical compensation strategies aimed at retaining talent and incentivizing performance in growth-oriented sectors.

Comparison to Industry Standards

• The specific size (791,885 shares) and exercise price ($2.46) of this option grant would need to be compared against similar-sized biotechnology companies, particularly those in early-stage development or with comparable market capitalizations, to assess if it is within industry norms for CEO compensation packages.
• The vesting schedule (50% immediate, remainder over two years) is a common structure, balancing immediate reward with long-term retention incentives, often seen in executive compensation plans across various industries.
• The 15.5% beneficial ownership stake for a CEO is a significant percentage, potentially higher than average for CEOs in larger, more mature companies, but could be more common in smaller, development-stage biotechnology firms where founders or key executives often hold substantial equity.

Corporate Governance

Related Party Transactions

• The grant of an Incentive Stock Option for 791,885 shares to Lance Alstodt, who serves as the Chief Executive Officer, President, and Chairman of the Board, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if the CEO's incentives lead to increased share price, but also potential for future dilution upon option exercise.
• Employees: No direct impact mentioned, but a well-incentivized leadership team can positively influence overall company direction and stability.
• Management: The CEO receives a significant long-term incentive, aligning his personal financial success with the company's performance.

Next Steps

• The CEO, Lance Alstodt, may exercise the vested portions of the option at any time until the expiration date of February 14, 2035.
• The remaining 50% of the option shares will continue to vest quarterly, with the first installment commencing one year from the grant date (February 14, 2026).
• The company will issue shares upon proper exercise of the options and payment of the exercise price and applicable taxes.

Key Dates

Recommendation

Keywords

BioRestorative Therapies, BRTX, Stock Option, Incentive Stock Option, CEO Compensation, Executive Compensation, Schedule 13D, Beneficial Ownership, Equity Grant, Vesting Schedule, Corporate Governance, Biotechnology, Healthcare